Aim: The modality of anticancer drug combinations needs to be renovated from empirical
into technical-supportive systems.
Methods: To challenge past therapeutic routines, the new landscape may be established. Among the
different areas of anticancer drug combination study, research in the fields of medical study is the
most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/
molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data
analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.
Discussion: This article addresses these types of cancer therapeutic management systems for clinical
anticancer drug combination utilities.
Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.